WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Wilson Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
INDUSTRY OUTLOOK
Globenewswire | May 19, 2023
Mustang Bio, Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (...
CELL AND GENE THERAPY
c-LEcta | December 20, 2021
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021. The high expectations for the fiscal year have been fully met and were even significantly exceeded. Thus, the management expects annual revenue in the range of EUR 20 million, which equates to a doubling of last year’s result. With an expanded team, further investments in the product range and the ENESYZ technology platform are expected to keep ...
MEDICAL
NuclixBio | March 15, 2022
NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™...
AVM Biotechnology | July 09, 2020
Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...
Article
MEDTECH
infographic
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE